Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06793982 · ClinicalTrials.gov registry record · Phase 4

Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

A Phase 4 study of Hip Osteoarthritis, sponsored by LifeBridge Health.

Recruiting
Registry status
Phase 4
Development phase
54
Enrollment target
1
Study location

NCT06793982 is a Phase 4 study of Hip Osteoarthritis that is actively recruiting participants, run by LifeBridge Health. The registered enrollment target is 54 participants, below the 400-participant average among 11 other Hip Osteoarthritis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06793982, a Phase 4 study of Hip Osteoarthritis, is actively recruiting participants, sponsored by LifeBridge Health.

RECRUITING
Registry status
Phase 4
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Conditions Studied

Interventions

  • DRUG Corticosteroid Injection
  • DEVICE Platelet Rich Plasma Joint Injection

Study Locations (1)

Maryland

  • Sinai Hospital of Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2024-02-21
Est. Completion 2025-12-01
Phase Phase 4

Sponsor

LifeBridge Health

14 total trials

What the Registry Record Tells You About NCT06793982

The ClinicalTrials.gov registry entry for NCT06793982 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 400-participant average among 11 other Hip Osteoarthritis trials with a reported enrollment target (86% lower). The listed sponsor is LifeBridge Health, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hip Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Corticosteroid Injection is the first listed.

NCT06793982 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT06793982 about?

NCT06793982 is a clinical study titled "Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain". Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient re...

What is the current status of trial NCT06793982?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2024-02-21. Estimated completion is 2025-12-01.

What conditions does trial NCT06793982 study?

This clinical trial studies the following conditions: Hip Osteoarthritis.

What interventions are being tested in trial NCT06793982?

The interventions under investigation include: Corticosteroid Injection (DRUG), Platelet Rich Plasma Joint Injection (DEVICE).

Who is sponsoring clinical trial NCT06793982?

This trial is sponsored by LifeBridge Health, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06793982 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hip Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.